论文部分内容阅读
目的:探讨重组人促卵泡激素(rhFSH)低剂量递增方案联合宫腔内人工授精(IUI)临床效果及卵巢反应预测因子。方法:选择多囊卵巢综合征、WHO II型排卵障碍及不明原因不孕患者60例,采用rhFSH(果纳芬)低剂量递增方案促排卵联合IUI,分析妊娠率、多胎妊娠率、卵巢过度刺激综合征(OHSS)发生率,并对卵巢反应预测因子加以分析。结果:①临床妊娠率28.21%,双胎妊娠率9.09%,流产率18.18%,促排卵过程中发生OHSS(轻度)1例,无三胎及以上妊娠。②促排卵成功患者与卵巢反应不良患者在体质量、体质量指数(BMI)、窦卵泡数(AFC)、rhFSH总剂量比较,差异均有统计学意义(P<0.05)。结论:rhFSH低剂量递增方案可以使排卵障碍特别是对其他促排卵药物抵抗患者获得较好的妊娠结局,促排卵结局可能受患者体质量、BMI、AFC等因素影响。
Objective: To investigate the clinical effect of low dose escalation of recombinant human follicle stimulating hormone (rhFSH) combined with intrauterine insemination (IUI) and predictors of ovarian response. Methods: Sixty women with polycystic ovary syndrome, WHO type II ovulation disorder and unexplained infertility were enrolled in this study. Pregnancy rate, multiple pregnancy rate, ovarian hyperstimulation Syndrome (OHSS) incidence, and ovarian response predictors were analyzed. Results: ① Clinical pregnancy rate was 28.21%, twin pregnancy rate was 9.09%, abortion rate was 18.18%. OHSS (mild) occurred during ovulation induction. There were no pregnancies with three or more pregnancies. ② There were significant differences in body mass, body mass index (AMI), total antral follicle count (AFC) and total rhFSH dose between patients with ovulation failure and those with ovarian dysfunction (P <0.05). CONCLUSIONS: The low dose escalation regimen of rhFSH can make ovulation disorders, especially for patients with other ovulation-inducing drugs, better pregnancy outcomes. The ovulation induction may be affected by body mass, BMI, AFC and other factors.